Ascentage Pharma Presents Positive Clinical Data for Olverembatinib and Lisaftoclax at EHA2026
Summary
Ascentage Pharma announced positive clinical updates for its two core drug candidates, olverembatinib and lisaftoclax, at the EHA2026 Congress, demonstrating efficacy across various blood cancers and strengthening their development programs.
Key Events
-
Olverembatinib in CML
Demonstrated deep and durable responses in chronic-phase CML (CML-CP) patients without the T315I mutation, supporting its potential as a second-line treatment option. Also showed positive data in CML patients with multiline TKI resistance and high-risk genetic mutations.
-
Olverembatinib in Ph+ ALL
Updated data from the global registrational Phase III study (POLARIS-1) showed robust clinical response, deep response rates, and a manageable safety profile in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
-
Olverembatinib + Lisaftoclax Combination
An open-label Phase Ib study showed encouraging preliminary efficacy and safety for this chemotherapy-free oral dual-targeted regimen in pediatric patients with relapsed/refractory (R/R) Ph+ ALL, achieving an 88.9% overall response rate.
-
Lisaftoclax in Myeloid Neoplasms
Real-world data demonstrated promising efficacy and manageable safety, particularly in acute myeloid leukemia (AML) patients, with a 72% complete remission/complete remission with incomplete hematologic recovery (CR/CRi) rate.
Analysis
Ascentage Pharma reported encouraging clinical data for its key drug candidates, olverembatinib and lisaftoclax, across multiple hematologic malignancies at the EHA2026 Congress. The updates reinforce the potential of olverembatinib as a second-line treatment for CML and in combination for Ph+ ALL, while lisaftoclax showed promising real-world efficacy in myeloid neoplasms and provided insights for CLL/SLL treatment. These positive results, especially while the stock trades near 52-week lows, could provide a boost to investor confidence in the company's pipeline and ongoing registrational studies.
At the time of this filing, AAPG was trading at $17.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $16.92 to $48.45. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.